Similarly, Li et al. demonstrated that GAS5 downregulation led to trastuzumab resistance in breast cancer, and the resistance could be alleviated by lapatinib which inhibits PI3K/Akt/mTOR pathway and eventually upregulates GAS5 (27). This evidence concerns the gene AKT1 and breast cancer.